Effects of the Insulin Sensitizer Pioglitazone on Menstrual Irregularity, Insulin Resistance and Hyperandrogenism in Young Women with Polycystic Ovary Syndrome

详细信息    查看全文

• 作者：Gaspare Stabile ; PhD¹ ; Irene Borrielli² ; ^{ireneborrielli@libero.it" class="auth_mail} ; Alfredo Carducci Artenisio ; MD¹ ; Lucia Maria Bruno¹ ; Salvatore Benvenga ; MD¹ ; Loretta Giunta ; MD¹ ; Antonio La Marca ; MD³ ; Annibale Volpe ; MD³ ; Alfonsa Pizzo ; MD²
• 关键词：Polycystic ovary syndrome ; Insulin resistence ; Adiponectin ; Pioglitazone
• 刊名：Journal of Pediatric and Adolescent Gynecology
• 出版年：June 2014
• 年：2014
• 卷：27
• 期：3
• 页码：177-182
• 全文大小：180 K

文摘

Polycystic ovary syndrome (PCOS) is the most common endocrine cause of menstrual irregularities, hirsutism and acne. Women with PCOS present elevated plasma insulin levels, both fasting and after a glucose load, as an indirect evidence of insulin resistance. PCOS women may also present hypertension, low levels of HDL cholesterol, hypertriglyceridemia, visceral obesity and a higher level of CRP and fibrinogen that can predict an atherosclerotic risk.

Methods

This study was carried out on 15 young women with PCOS selected according to the 2003 diagnostic criteria of The Rotterdam Consensus Statement and 15 Control women. PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17尾-estradiol, free and total testosterone, SHBG, DHEA-S, 螖4-androstenedione and adiponectin.

Results and Discussion

Treatment with pioglitazone improves the irregularities of menses and hirsutism. Six months of treatment modify other parameters linked with a higher risk of type 2 diabetes mellitus and cardiovascular diseases: adiponectin increased with reduction of insulin resistance while fibrinogen and CRP levels decreased.